- NCIt
- C3512
- OncoTree
- LUAD
- DOID
- 3910
- UMLS CUI
- C0152013
- MeSH
- D000077192
Loading cancer entity…
Loading cancer entity…
Clinical trials
231 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (28)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 170 | NRG OncologyOTHER | 3 | Jul 13, 2026 | clinicaltrials |
| NCT03184571 | Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 99 | BerGenBio ASAINDUSTRY | 4 | Sep 25, 2025 | clinicaltrials |
| NCT01737502 | Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 29 | Mayo ClinicOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT03845296 | Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | completed | Phase 2 | 64 | SWOG Cancer Research NetworkNETWORK | 1 | May 21, 2025 | clinicaltrials |
| NCT02264210 | Icotinib for Completed Resected IB NSCLC With EGFR Mutation(CORIN) | completed | Phase 2 | 128 | Sun Yat-sen UniversityOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04770688 | Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib(AUTOMAN) | completed | Phase 1 / Phase 2 | 25 | Shanghai Chest HospitalOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT02759835 | Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 7, 2024 | clinicaltrials |
| NCT03076164 | A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib | completed | Phase 1 / Phase 2 | 24 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04310943 | Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in Lung Adenocarcinoma | completed | Phase 2 | 24 | Zhou ChengzhiOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02980991 | Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma (ECTOP-1002) | completed | Phase 2 | 80 | Fudan UniversityOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT03904563 | Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma | completed | Phase 2 | 27 | Sun Yat-sen UniversityOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT04201756 | Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma | completed | Phase 2 | 47 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT01935336 | Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers | completed | Phase 2 | 171 | University of Colorado, DenverOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT02303977 | Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy | completed | Phase 2 | 37 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Sep 29, 2021 | clinicaltrials |
| NCT02276027 | A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 66 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 16, 2020 | clinicaltrials |
| NCT00950365 | Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 79 | Albert Einstein College of MedicineOTHER | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01218516 | A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung | completed | Phase 2 | 130 | MorphotekINDUSTRY | 8 | Aug 20, 2020 | clinicaltrials |
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT03704870 | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT03544814 | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression | completed | Phase 2 | 99 | Shanghai Chest HospitalOTHER | 0 | Oct 15, 2019 | clinicaltrials |
| NCT01259089 | Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT00126581 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01362790 | SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2019 | clinicaltrials |
| NCT01557959 | Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 45 | Wake Forest University Health SciencesOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT02979821 | Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) | completed | Phase 2 | 6 | Korean Association for the Study of Targeted TherapyOTHER | 1 | May 24, 2018 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT00368992 | S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2015 | clinicaltrials |
| NCT00716456 | Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00511485 | Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) | completed | Phase 2 | 43 | EndocyteINDUSTRY | 0 | Feb 27, 2015 | clinicaltrials |
| NCT00384826 | Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma | completed | Phase 2 | 133 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01578668 | Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases | completed | Phase 2 | 69 | Guangzhou Medical UniversityOTHER | 1 | Jan 26, 2015 | clinicaltrials |
| NCT00118144 | Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer | completed | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01561456 | Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung | completed | Phase 2 | 100 | Axelar ABINDUSTRY | 5 | Dec 5, 2013 | clinicaltrials |
| NCT00040794 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00029003 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00021060 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 842 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jul 13, 2026source: clinicaltrials